J.P. Morgan Securities discloses dealings in Kangji Medical shares

On September 19, 2025, J.P. Morgan Securities PLC disclosed its dealings in Kangji Medical Holdings Limited shares, as per Rule 22 of the Hong Kong Code on Takeovers and Mergers. The transactions occurred on September 18, 2025, as part of a privatization via scheme of arrangement.

J.P. Morgan Securities PLC undertook two separate purchase transactions involving "other types of securities (e.g. equity swaps)," used for hedging Delta 1 products from unsolicited client orders. The first purchase involved 78,000 shares at a total cost of $695,423.4800, with prices ranging from $8.9300 to $8.8700 per share.

A second purchase involved 10,000 shares for $89,041.0000, with both the highest and lowest prices recorded at $8.8952 per share. J.P. Morgan Securities PLC, a Class (5) associate connected with the Offeror and ultimately owned by JPMorgan Chase & Co., confirmed these dealings were made for its own account.